KEY FEATURES
| Full Name | Cluster Of Differentiation 19 |
|---|---|
| Synonym | B4; B-lymphocyte surface antigen B4; T-cell surface antigen Leu-12 |
| Assay Type | Sandwich |
| Reactivity | Human |
| Range | 0.31-20ng/mL |
| Sensitivity | 0.12ng/mL |
| Sample Type | Serum,plasma and other biological fluids |
| Sample Volume | 100μL |
| Detection Wavelength | OD450 |
| Transportation Temperature | 2-8°C |
| Specificity | The kit detected Human CD19 in the samples and no significant cross-species reactions were found |
| Microplate | 96-wells plate breakable into 12 x 8 wells strip |
TEST PRINCIPLE
| This ELISA kit uses the Sandwich-ELISA principle. The micro ELISA plate provided in this kit has been pre-coated with an antibody specific to Human CD19. Standards or samples are added to the micro ELISA plate wells and combined with the specific antibody. Then a biotinylated detection antibody specific for Human CD19 and Avidin-Horseradish Peroxidase (HRP) conjugate are added successively to each micro plate well and incubated. Free components are washed away. The substrate solution is added to each well. Only those wells that contain Human CD19, biotinylated detection antibody and Avidin-HRP conjugate will appear blue in color. The enzyme-substrate reaction is terminated by the addition of stop solution and the color turns yellow. The optical density (OD) is measured spectrophotometrically at a wavelength of 450 nm ± 2 nm. The OD value is proportional to the concentration of Human CD19. You can calculate the concentration of Human CD19 in the samples by comparing the OD of the samples to the standard curve. |
ELISA KIT COMPONENTS
Upon receipt, unpack promptly and store as recommended in the instructions.
| Components | Specifications | Storage and Notes |
|---|---|---|
| Micro Plate | 96T: 8 wells×12 strips 48T: 8 wells×6 strips | Unopened: -20°C, 12 months Unused: Put it back in the aluminum foil bag and seal it, store it at -20°C. |
| Reference Standard | 96T: 2 vials 48T: 1 vial | Unopened: -20°C, 12 months Please use freshly dissolved standards for each experiment. Discard any unused standards after dissolution. |
| Biotinylated Detection Ab Concentrate (100×) | 96T: 120μL×1 vial 48T: 60μL×1 vial | Unopened: -20°C, 12 months Unused: Please seal the concentrate and store it at -20°C, and discard the working solution. |
| HRP Conjugate Concentrate (100×) | 96T: 120μL×1 vial 48T: 60μL×1 vial | Unopened: -20°C(Protect from light), 12 months Unused: Please seal the concentrate and store it at -20°C, and discard the working solution. |
| Biotinylated Detection Ab Diluent | 14mL×1 | 2-8℃, 12 months |
| HRP Conjugate Diluent | 14mL×1 | 2-8℃, 12 months |
| Reference Standard & Sample Diluent | 20mL×1 | 2-8℃, 12 months |
| Washing Buffer Concentrate (25×) | 30mL×1 | 2-8℃, 12 months |
| Substrate Reagent(TMB) | 10mL×1 | 2-8°C(Protect from light),12 months |
| Stop Solution | 7mL×1 | 2-8°C/Room temperature |
ASSAY PROCEDURES

TYPICAL DATA

Human CD19 ELISA Standard Curve
Typical data are for reference only and curves should be replotted for each experiment. The Logistics function is recommended for fitting.
PRECISION
Intra-Assay Precision (Precision within an assay): Three samples of known concentration were tested twenty times on one plate to assess intra-assay precision.
Inter-Assay Precision (Precision between assays): Three samples of known concentration were tested in twenty separate assays to assess inter-assay precision. Assays were performed by at least three technicians using two lots of components.
| Intra-assay Precision | Inter-assay Precision | |||||
|---|---|---|---|---|---|---|
| Sample | 1 | 2 | 3 | 1 | 2 | 3 |
| n | 20 | 20 | 20 | 20 | 20 | 20 |
| Mean (ng/mL) | 0.91 | 1.89 | 9.52 | 0.92 | 1.81 | 9.36 |
| Standard deviation | 0.06 | 0.09 | 0.47 | 0.06 | 0.08 | 0.39 |
| CV(%) | 6.42 | 4.89 | 4.91 | 6.73 | 4.42 | 4.19 |
RECOVERY
The recovery of Human CD19 spiked to three different levels in samples throughout the range of the assay in various matrices was evaluated.
| Sample Type | Range (%) | Average Recovery (%) |
|---|---|---|
| Serum(n=8) | 91-107 | 99 |
| EDTA plasma (n=8) | 88-103 | 95 |
| Cell culture media (n=8) | 93-108 | 101 |
LINEARITY
To assess the linearity of the assay, samples containing and/or spiked with high concentrations of Human CD19 in various matrices were diluted with the Reference Standard & Sample Diluent to produce samples with values within the dynamic range of the assay.

Products associated with CD19 ELISA Kits
| CD22 ELISA Kit | publications with CD19 and CD22 |
| CD79A ELISA Kit | publications with CD19 and CD79A |
| CD79B ELISA Kit | publications with CD19 and CD79B |
| CD81 ELISA Kit | publications with CD19 and CD81 |
| CR2 ELISA Kit | publications with CD19 and CR2 |
| LYN ELISA Kit | publications with CD19 and LYN |
| SYK ELISA Kit | publications with CD19 and SYK |
| BTK ELISA Kit | publications with CD19 and BTK |
| VAV1 ELISA Kit | publications with CD19 and VAV1 |
Pathways associated with CD19 ELISA Kit
| Adaptive Immune System Pathway | Adaptive Immune System Pathway |
| Antigen Activates B Cell Receptor (BCR) Leading To Generation Of Second Messengers Pathway | Antigen Activates B Cell Receptor (BCR) Leading To Generation Of Second Messengers Pathway |
| B Cell Receptor Signaling Pathway | B Cell Receptor Signaling Pathway |
| BCR Signaling Pathway | BCR Signaling Pathway |
| Constitutive PI3K/AKT Signaling In Cancer Pathway | Constitutive PI3K/AKT Signaling In Cancer Pathway |
| DAP12 Interactions Pathway | DAP12 Interactions Pathway |
| DAP12 Signaling Pathway | DAP12 Signaling Pathway |
| Disease Pathway | Disease Pathway |
Diseases associated with CD19 ELISA Kit
| Cardiovascular Diseases | publications with CD19 and Cardiovascular Diseases |
| Inflammation | publications with CD19 and Inflammation |
| Respiratory Tract Diseases | publications with CD19 and Respiratory Tract Diseases |
| Necrosis | publications with CD19 and Necrosis |
| Death | publications with CD19 and Death |
| Lung Diseases | publications with CD19 and Lung Diseases |
| Liver Diseases | publications with CD19 and Liver Diseases |
| Cell Transformation, Neoplastic | publications with CD19 and Cell Transformation, Neoplastic |
| Respiratory Tract Infections | publications with CD19 and Respiratory Tract Infections |
| Asthma | publications with CD19 and Asthma |
Organs/Tissues associated with CD19 ELISA Kit
| Blood | publications with CD19 and Blood |
| Bone Marrow | publications with CD19 and Bone Marrow |
| Spleen | publications with CD19 and Spleen |
| Lymph Node | publications with CD19 and Lymph Node |
| Lymph | publications with CD19 and Lymph |
| Lung | publications with CD19 and Lung |
| Thymus | publications with CD19 and Thymus |
| Brain | publications with CD19 and Brain |
| Tonsil | publications with CD19 and Tonsil |
| Intestine | publications with CD19 and Intestine |